gilead hiv - Search News

News

FDA Approves HIV Shot That’s 99.9% Effective

Barron's on MSN · 3d

FDA Approves Gilead’s HIV Shot. It Works 99.9% of the Time.

The Food and Drug Administration approved a twice-yearly shot that prevented HIV infections in 99.9% of the people who received it in large clinical trials. The drug, developed by Gilead Sciences and called Yeztugo,

USA TODAY on MSN · 2d

FDA approves new twice-yearly HIV shot. What to know

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show prevents new infections.

CNBC on MSN · 3d

FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option

The launch of the injection faces potential threats, including the Trump administration's proposed cuts to federal funding for HIV prevention efforts.

HIV prevention drug lenacapavir gets FDA nod, nearly 100 per cent effective says experts

HIV targets the white blood cells and weakens the immune system. This would make the person prone to diseases like ...

Fierce Pharma3d

FDA signs off on Gilead's landmark long-acting PrEP med, signaling new era in HIV prevention

With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo ...

Pharmalittle: We’re reading about FDA forcing out top gene therapy regulator, Gilead’s HIV challenges and more

And more pharma news updates from Pharmalittle.

2d

US approves twice-yearly HIV jab in ‘breakthrough moment’ for fight against Aids

The United States has approved a twice-a-year jab that almost entirely protects against HIV in what’s being hailed as a ...

5don MSN

Gilead (GILD) Downplays FDA Decision to Pause HIV Combination Trial over Safety Concern

Gilead Sciences Inc. (NASDAQ:GILD) is one of the 12 best healthcare stocks to buy now. Nevertheless, the company suffered a ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results